Robert Feldman
Robert is a biotech executive, board member and advisor. He has experience founding startups, working in rapidly scaling growth companies leading to IPOs and helping position large international companies moving through M&As. His domain expertise includes business development, strategy, competitive analysis, operations, investor relations, board management, program management and development of diagnostics, biotech, genomics, NGS, bioinformatics, products and services for medical genetics and cancer, clinical collaborations, diagnostics, and the microbiome.
He is currently SVP of Business Development at Fluxus Inc., a Silicon Valley company recently acquired by Fujirebio Inc, a global diagnostics leader. Fluxus is developing and commercializing biochip-based, opto-fluidic, single molecule detection platforms for ultra-high sensitivity diagnostics and biosensor applications.
Robert has held leadership positions in several biotech and genomics based companies including as CEO of Prime Genomics (cancer diagnostics). Centrillion and SymBio (genomics services) and Amersham (genomics technology products) and Diversa Corp (environmental metagenomics).
His work in microbial genomics of deep sea hydrothermal vent organisms, ecological metagenomics and human microbiomics has resulted in seminal, high profile, high impact works co-authored and published in Nature, Science and PNAS. From a list of over 40 publications, In total, these publications have over 12,000 citations.
Robert holds a PhD in Genetics from the University of Hawaii and BS/MS degrees in Biological Sciences from the University of Illinois.